Evidence map›Paper›PMID 39456213›Full record

ReviewBiomolecules2024

[

Jolien Zwama, Neeltje M Rosenberg, Vincent A Verheij, Pieter G H M Raijmakers, Maqsood Yaqub, Esmée Botman, Ruben D de Ruiter, Mark R Garrelfs, Arend Bökenkamp, Dimitra Micha and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jolien ZwamaAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.ORCID 0009-0007-4365-3625
Neeltje M RosenbergAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.
Vincent A VerheijAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.ORCID 0000-0002-2040-5473
Pieter G H M RaijmakersRare Bone Disease Centre, Amsterdam, The Netherlands.
Maqsood YaqubRare Bone Disease Centre, Amsterdam, The Netherlands.
Esmée BotmanAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.
Ruben D de RuiterAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.ORCID 0000-0002-5035-9199
Mark R GarrelfsRare Bone Disease Centre, Amsterdam, The Netherlands.
Arend BökenkampRare Bone Disease Centre, Amsterdam, The Netherlands.ORCID 0000-0002-3492-2252
Dimitra MichaAmsterdam Movement Sciences, Tissue Function and Regeneration, Amsterdam, The Netherlands.ORCID 0000-0001-7890-4411
Lothar A SchwarteRare Bone Disease Centre, Amsterdam, The Netherlands.ORCID 0000-0001-6119-7810
Bernd P TeunissenRare Bone Disease Centre, Amsterdam, The Netherlands.
Adriaan A LammertsmaRare Bone Disease Centre, Amsterdam, The Netherlands.ORCID 0000-0003-1237-2891
Ronald BoellaardRare Bone Disease Centre, Amsterdam, The Netherlands.
Elisabeth M W EekhoffAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.ORCID 0000-0001-5399-676X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plasma-soluble biomarkers for flare-ups or heterotopic bone formation poses severe challenges to the monitoring of disease activity to measure or predict disease progression. Recently, 18-fluor-sodium fluoride positron emission tomography/computed tomography ([

Indexed as

BiomarkersFluorine RadioisotopesMyositis OssificansPositron Emission Tomography Computed TomographySodium FluorideAnimalsHumansBiomarkersFluorine-18Fluorine RadioisotopesSodium Fluoride18F-sodium fluoride (18F-NaF)fibrodysplasia ossificans progressivaheterotopic ossificationmusculoskeletal developmentosteoblastspositron emission tomography/computed tomography (PET/CT)rare bone diseases

Identifiers

PMID39456213
PMCPMC11505869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.